Similar articles

• Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.

  Labenz J, Stolte M, Peitz U, Tillenburg B, Köhl H, Becker T, Börsch G. Labenz J, et al. Z Gastroenterol. 1995 Oct;33(10):590-3. Z Gastroenterol. 1995. PMID: 7502551 Clinical Trial.
• Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.

  Laine L, Estrada R, Trujillo M, Emami S. Laine L, et al. Am J Gastroenterol. 1997 Dec;92(12):2213-5. Am J Gastroenterol. 1997. PMID: 9399755 Clinical Trial.
• One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.

  Kung NN, Sung JJ, Yuen NW, Li TH, Ng PW, Lai WM, Lui YH, Lam KN, Choi CH, Leung EM. Kung NN, et al. Am J Gastroenterol. 1999 Mar;94(3):721-4. doi: 10.1111/j.1572-0241.1999.00942.x. Am J Gastroenterol. 1999. PMID: 10086657 Clinical Trial.
• Triple therapy and Helicobacter pylori.

  Davis S. Davis S. Aust Fam Physician. 1996 Jan;25(1):53, 56-9. Aust Fam Physician. 1996. PMID: 8607776 Review.
• Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use?

  de Boer WA, Kuipers EJ, Kusters JG. de Boer WA, et al. Dig Liver Dis. 2004 May;36(5):311-4. doi: 10.1016/j.dld.2004.01.016. Dig Liver Dis. 2004. PMID: 15191198 Review. No abstract available.